What changed

First Phase 2 trial on record: NCT07749716 — Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

Approved by the European Commission for severe alopecia areata in adults and adolescents from 12. Still under FDA review in the US.

First Phase 3 trial on record: NCT07516561 — Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia

First Phase 2 trial on record: NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

First Phase 3 trial on record: NCT07435012 — Androgenic Alopecia TH07 Clinical Trial

Registered on ClinicalTrials.gov as NCT07618195: Study of EPI-001 in Patients With Androgenetic Alopecia

First Phase 2 trial on record: NCT07311564 — A Study of LAD603 in Adults With Alopecia Areata

First Phase 1/2 trial on record: NCT07327359 — A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

First Phase 1/2 trial on record: NCT07317544 — Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia

First Phase 2 trial on record: NCT06562894 — Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients

First Phase 2 trial on record: NCT07011485 — A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.

First Phase 3 trial on record: NCT06916793 — A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

First Phase 1/2 trial on record: NCT06826196 — A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

First Phase 3 trial on record: NCT06972264 — Safety and Efficacy of VDPHL01 in Males With AGA

First Phase 3 trial on record: NCT06501924 — Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss

First Phase 3 trial on record: NCT05824065 — Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss

First Phase 2/3 trial on record: NCT06724614 — Efficacy and Safety of VDPHL01 in Males With AGA

First Phase 3 trial on record: NCT05888922 — Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

First Phase 2 trial on record: NCT06104839 — Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata

First Phase 2 trial on record: NCT06527365 — Safety and Efficacy of VDPHL01 in Males and Females With AGA

First Phase 2 trial on record: NCT06444451 — A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

First Phase 2 trial on record: NCT06393452 — Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

First APPROVED trial on record: NCT06240351 — A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

First Phase 2 trial on record: NCT06340360 — A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

First Phase 3 trial on record: NCT06012240 — A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

First Phase 1/2 trial on record: NCT06060977 — A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

First Phase 2 trial on record: NCT06018428 — A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

First Phase 2 trial on record: NCT06118866 — A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

First Phase 3 trial on record: NCT05910450 — A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

First Phase 2 trial on record: NCT05865041 — Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

First Phase 2 trial on record: NCT06692465 — To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males

First Phase 2 trial on record: NCT05778825 — A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors

First Phase 2 trial on record: NCT05802173 — Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

First Phase 3 trial on record: NCT04880889 — BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.

First Phase 2 trial on record: NCT05677438 — A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

First Phase 1/2 trial on record: NCT05636904 — Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men

First Phase 2 trial on record: NCT05496426 — A Study of KL130008 in Adults With Severe Alopecia Areata

First Phase 2 trial on record: NCT05556265 — A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

First Phase 2 trial on record: NCT04011748 — Clinical Application of Stem Cell Educator Therapy in Alopecia Areata

First Phase 1 trial on record: NCT05324293 — To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period

First Phase 2 trial on record: NCT05368103 — Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

First Phase 3 trial on record: NCT05470413 — Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

First Phase 2 trial on record: NCT06402630 — A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)

First Phase 3 trial on record: NCT06126965 — Phase III Study of KX-826 With Adult Male Patients With AGA

First Phase 2 trial on record: NCT05205070 — A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata

First Phase 2 trial on record: NCT03532958 — Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata

First Phase 1/2 trial on record: NCT04945226 — A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001

First Phase 3 trial on record: NCT05051761 — Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

First Phase 1 trial on record: NCT06468579 — To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects

First Phase 3 trial on record: NCT04825561 — A Study to Evaluate the Efficacy and Safety of AD-208

First Phase 1 trial on record: NCT04805606 — A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843

First Phase 1 trial on record: NCT04913519 — A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

First Phase 3 trial on record: NCT04518995 — Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

First Phase 2 trial on record: NCT05940506 — Phase II Study Evaluating the Efficacy and Safety of KX-826

First Phase 2 trial on record: NCT04556734 — Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

First Phase 2 trial on record: NCT04346316 — A Phase II Study in Patients With Alopecia Areata

First Phase 1 trial on record: NCT04214808 — To Evaluate the Pharmacokinetics and Safety of AD-208

First Phase 2 trial on record: NCT04034134 — Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata

First Phase 3 trial on record: NCT04006457 — Long-Term PF-06651600 for the Treatment of Alopecia Areata

First Phase 3 trial on record: NCT03899259 — A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

First Phase 2/3 trial on record: NCT03898479 — Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

First Phase 1 trial on record: NCT04984707 — Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

First Phase 2/3 trial on record: NCT03732807 — PF-06651600 for the Treatment of Alopecia Areata

First Phase 2/3 trial on record: NCT03742518 — A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia

First Phase 2/3 trial on record: NCT03570749 — A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

First Phase 2 trial on record: NCT03594227 — ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

First Phase 2 trial on record: NCT03351322 — ENERGI-F701 for Female Hair Loss Treatment

First Phase 2 trial on record: NCT03467412 — To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin

First Phase 2 trial on record: NCT03354637 — A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata

First Phase 2 trial on record: NCT03137381 — Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

First Phase 2 trial on record: NCT02636244 — Safety and Efficacy Study of SHAPE Gel in Alopecia Areata

First Phase 2 trial on record: NCT02974868 — Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

First Phase 2 trial on record: NCT02974868 — Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

First Phase 2 trial on record: NCT02919735 — Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)

First Phase 3 trial on record: NCT03004469 — Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia

First Phase 2 trial on record: NCT02781311 — A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

First Phase 1/2 trial on record: NCT02793557 — Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth

First Phase 2 trial on record: NCT02561585 — LEO 124249 Ointment in the Treatment of Alopecia Areata

First Phase 2 trial on record: NCT02553330 — A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

First Phase 2 trial on record: NCT02275351 — A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

First Phase 2 trial on record: NCT02279823 — A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

First Phase 1/2 trial on record: NCT01673789 — Stem Cell Educator Therapy in Alopecia Areata

First Phase 1/2 trial on record: NCT01501617 — Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia

First Phase 2 trial on record: NCT01325337 — Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

First Phase 1/2 trial on record: NCT01286649 — Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia

First Phase 1 trial on record: NCT01189279 — Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

First Phase 2 trial on record: NCT01451021 — A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss

First Phase 2 trial on record: NCT00418730 — Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss

First Phase 3 trial on record: NCT00441116 — A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia